Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05958992 · ClinicalTrials.gov registry record · NA
Effects of e-Cigarettes on Perceptions and Behavior - Remote Substudy # 2
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 461
- Enrollment target
NCT05958992: Completed NA study, sponsored by University of Southern California.
NCT05958992 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 461 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05958992, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 461 participants
- Enrollment target
Study Summary
This study assess the ways in which e-cigarette product characteristics, such as flavors and nicotine salts, impact user experience to inform potential regulations.
Primary Outcome
This self-report measures of subjective product appeal will be completed following e-cigarette self-administration. Scores can range from 0 to 100 for the appeal rating, with lower scores representing lower levels of appeal and higher scores representing higher levels of appeal.
Interventions
- OTHER E-cigarette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2022-05-01 |
| Phase | NA |
What the finished NCT05958992 record still lists
NCT05958992 is an interventional study that assigns participants to a tested intervention. The registered 461 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which E-cigarette is the first listed.
NCT05958992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05958992 about?
NCT05958992 is a clinical study titled "Effects of e-Cigarettes on Perceptions and Behavior - Remote Substudy # 2". This study assess the ways in which e-cigarette product characteristics, such as flavors and nicotine salts, impact user experience to inform potential regulations.
What is the current status of trial NCT05958992?
This trial is currently completed. It is a NA study. The enrollment target is 461 participants. The study started on 2020-08-25. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT05958992?
The interventions under investigation include: E-cigarette (OTHER).
Who is sponsoring clinical trial NCT05958992?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05958992's enrollment target sits among peer trials
461 222nd of 2000 higher than 1,779 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI